FDA Releases Guidance on Vial Fill Size - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Releases Guidance on Vial Fill Size


FDA has released guidance that clarifies the agency’s current thinking on allowable excess volume and labeled vial-fill size in injectable drug and biological products. The draft guidance document states FDA’s requirements and recommendations in regards to allowable excess volume in vials. The guidance also explains when justification is needed for a proposed excess volume in these injectable drug products.

The Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) point out the importance of appropriate packaging sizes for injectable drug products in the guidance. The agencies recommend that labeled vial fill sizes be appropriate for the intended use and dosing of the drug product.

Fill and packaging issues for injectable drug products that are packaged in vials and ampules, including products that require reconstitution, are addressed in the guidance. Injectable drug products in other packaging types (e.g., prefilled syringe package systems and intravenous infusion bags) or noninjectable products are not covered in the guidance because there may be unique considerations for these packaging configurations. FDA states that the guidance applies to new drug applications, abbreviated new drug applications, biologics license applications, and new packaging supplements to these existing applications submitted to CDER and CBER.

Source: FDA.gov

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here